Susquehanna International Group’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-549,877
| Closed | -$18.4M | – | 14433 |
|
|
2026
Q1 | $18.4M | Buy |
549,877
+305,519
| +125% | +$12M | ﹤0.01% | 2336 |
|
|
2025
Q4 | $11.3M | Buy |
244,358
+228,340
| +1,426% | +$12.5M | ﹤0.01% | 2895 |
|
|
2025
Q3 | $1.08M | Sell |
16,018
-396,689
| -96% | -$29.4M | ﹤0.01% | 7172 |
|
|
2025
Q2 | $34.6M | Buy |
412,707
+362,433
| +721% | +$27.1M | ﹤0.01% | 1465 |
|
|
2025
Q1 | $3.59M | Buy |
50,274
+23,742
| +89% | +$1.16M | ﹤0.01% | 4298 |
|
|
2024
Q4 | $1.19M | Buy |
26,532
+14,824
| +127% | +$768K | ﹤0.01% | 6524 |
|
|
2024
Q3 | $591K | Sell |
11,708
-27,476
| -70% | -$1.32M | ﹤0.01% | 8062 |
|
|
2024
Q2 | $1.6M | Buy |
39,184
+30,162
| +334% | +$1.28M | ﹤0.01% | 5532 |
|
|
2024
Q1 | $386K | Sell |
9,022
-12,598
| -58% | -$570K | ﹤0.01% | 9113 |
|
|
2023
Q4 | $870K | Buy |
+21,620
| New | +$615K | ﹤0.01% | 7332 |
|
|
2023
Q1 | – | Sell |
-11,545
| Closed | -$22.9K | – | 13425 |
|
|
2022
Q4 | $22.9K | Buy |
+11,545
| New | +$14.4K | ﹤0.01% | 11716 |
|
|
2022
Q3 | – | Sell |
-1,123
| Closed | -$2.73K | – | 14046 |
|
|
2022
Q2 | $3K | Buy |
1,123
+145
| +15% | +$401 | ﹤0.01% | 12661 |
|
|
2022
Q1 | $3K | Sell |
978
-8,138
| -89% | -$42.1K | ﹤0.01% | 12853 |
|
|
2021
Q4 | $56K | Buy |
9,116
+2,056
| +29% | +$21.6K | ﹤0.01% | 12487 |
|
|
2021
Q3 | $97K | Sell |
7,060
-472
| -6% | -$6.58K | ﹤0.01% | 12093 |
|
|
2021
Q2 | $129K | Buy |
7,532
+2,452
| +48% | +$41.4K | ﹤0.01% | 11943 |
|
|
2021
Q1 | $96K | Buy |
5,080
+2,498
| +97% | +$80.5K | ﹤0.01% | 11880 |
|
|
2020
Q4 | $75K | Buy |
2,582
+105
| +4% | +$3.03K | ﹤0.01% | 10619 |
|
|
2020
Q3 | $93K | Buy |
+2,477
| New | +$72.4K | ﹤0.01% | 9953 |
|
|
2020
Q2 | – | Sell |
-5,158
| Closed | -$224K | – | 10843 |
|
|
2020
Q1 | $184K | Buy |
5,158
+4,078
| +378% | +$174K | ﹤0.01% | 8786 |
|
|
2019
Q4 | $48K | Buy |
+1,080
| New | +$27.6K | ﹤0.01% | 9356 |
|
|
2018
Q1 | – | Sell |
-1,080
| Closed | -$29K | – | 10106 |
|
|
2017
Q4 | $29K | Buy |
+1,080
| New | +$31.1K | ﹤0.01% | 9027 |
|
|
2017
Q2 | – | Sell |
-396
| Closed | -$20K | – | 9777 |
|
|
2017
Q1 | $20K | Buy |
+396
| New | +$23.4K | ﹤0.01% | 8728 |
|
Susquehanna International Group's SLNO Position: Q2 2026 in Review
Susquehanna International Group sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 549,877 shares — an estimated $18.4M sold.
Susquehanna International Group first reported a position in SLNO in Q1 2017 and held it in 23 quarters. The position peaked at $34.6M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Susquehanna International Group reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Susquehanna International Group sold 549,877 Soleno Therapeutics shares in Q2 2026, an estimated $18.4M.
- Susquehanna International Group first reported a position in Soleno Therapeutics in Q1 2017 and held it in 23 quarters.
- Susquehanna International Group's Soleno Therapeutics position peaked at $34.6M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.